Blog

Blog Category


Control or Collaboration – Value Creation & Success Focus 
Posted on May 12, 2017

  The following commentary is from Mr. Tom Brya, Managing Director at Titenare GXL. Titenare is an international consultancy providing integrated, knowledge-based services and  solutions to pharma companies internationally. For further information, please visit www.titenaregxl.com. The pharma business model is rapidly moving towards a PwC 2009 prediction, which said that the industry will become collaboration-centric. This was


Biosimilars: Who wants to play this game? 
Posted on Apr 14, 2017

     A recent post by Robert Wessman of Alvogen pointed out that some companies are abandoning their efforts in the biosimilars markets. Amgen, for instance, recently decided to postpone the launch of a biosimilar version of adalimumab until litigation issues are resolved, which could take years (if ever). By the way, adalimumab is a


Visit to England: What Did We Learn? 
Posted on Apr 04, 2017

We just returned from a brief trip to England, where we met with a client, plus a few friends and colleagues. Over several meetings and meals, three issues consistently came up during conversation: Terrorism, Brexit and Trump. Terrorism – The United Kingdom is no stranger to terrorism, as this lengthy list of terrorist attacks in London illustrates. The

Google Plus   Facebook   Twitter
Powered By : Supra International Inc.